title: Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma.
abstract: Interleukin-17A (IL-17A) promotes the osteoclast (OC)-like differentiation of dendritic cells (DCs) in multiple myeloma (MM) and contributes to the pathogenesis of myeloma bone disease (MBD). In our study, everolimus (EVR) abrogated the in vitro OC-like activity of DCs from 12 MM patients significantly. Exploring the EVR effects, we found that the inhibition of the osteoerosive activity of OC-DCs was mostly due to the blockade of signals driven by the IL-17A receptor toward the CCAAT/enhancer-binding protein beta/musculoaponeurotic fibrosarcoma oncogene homolog B axis Therefore, MM patients with MBD would probably benefit from mammalian target of rapamycin inhibition.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy. Electronic address: marco.tucci@uniba.it.
authors.forename: Marco
authors.initials: M
authors.lastname: Tucci
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Stucci
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Passarelli
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
authors.forename: Stella
authors.initials: S
authors.lastname: D'Oronzo
authors.affiliation: Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Silvestris
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002448:Cell Adhesion / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D054338:Cell Transdifferentiation / Q000187:drug effects* / Q000235:genetics; D003713:Dendritic Cells / Q000378:metabolism* / Q000473:pathology; D000068338:Everolimus / Q000494:pharmacology* / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010010:Osteoclasts / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D020381:Interleukin-17; D000068338:Everolimus